St. George's respiratory questionnaire: MCID

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 2, Issue 1, 2005, Pages 75-79

  Jones, Paul W ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Clinical significance; Clinical trial; COPD; Health status; Health related quality of life

Indexed keywords

BRONCHODILATING AGENT; FORMOTEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

ANALYTIC METHOD; CALCULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC VALUE; EVIDENCE BASED MEDICINE; EXPERT SYSTEM; HEALTH STATUS; HUMAN; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; PATIENT SELECTION; PRIORITY JOURNAL; QUESTIONNAIRE; SAINT GEORGE RESPIRATORY QUESTIONNAIRE; STATISTICAL ANALYSIS;

DATA INTERPRETATION, STATISTICAL; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RESPIRATION; TREATMENT OUTCOME;

EID: 20144362569     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1081/COPD-200050513     Document Type: Conference Paper

References (21)

1. Jones PW, Bosh TK. Changes in quality of life in COPD patients treated with salmeterol. Am J Resp Crit Care Med 1997; 155:1283-1289.
2. Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, ZuWallack RL, Menjonge SS, Serby CW, Witek T. A long-term evaluation of once daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:209-216.
3. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ, Dutch/Belgian Tiotropium Study G. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19(2):209-216.
4. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:74-81.
5. Calverley PMA, Pauwels R, Vestbo J, Jones PW, Pride N, Gulsvick A. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. Lancet 2003; 361:449.
6. Calverley PMA, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:912-919.
7. Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, Turner-Lawlor PJ, Payne N, Newcombe RG, lonescu AA, Thomas J, Tunbridge J. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000; 355(9201):362-368.
8. National Emphysema Treatment Trial Research Group. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. NEJM 2003; 348:2092-2102.
9. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56:880-887.
10. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure for chronic airflow limitation-the St George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327.
11. Jones PW. Interpreting thresholds for a clinically significant changes in health status in asthma and COPD. Eur Respir J 2002; 19:398-404.
12. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85(suppl B):25-31.
13. Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997; 52:67-71.
14. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54(7):581-586.
15. Domingo-Salvany A, Lamarca R, Ferrer M, Garcia-Aymerich J, Alonso J, Fělez M, Khalaf A, Marrades RM, Monsó E, Serra-Batlles J, Antǒ JM. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:680-685.
16. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmnary disease. Am J Respir Crit Care Med 2003; 167:544-549.
17. Schunemann HJ, Griffith L, Jaeschke R, Goldstein RS, Stubbing D, Guyatt GH. Evaluation of the minumum important difference for the feeling thermometer and the St George's Respiratory Questionnaire in patients with chronic airflow limitation. J Clin Epidemiol 2003; 56:1170-1176.
18. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41:582-592.
19. Dahl R, Greefhorst LAPM, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:778-784.
20. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10:407-415.
21. Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care 2001; 39:1039-1047.